Pharmacologic Management of Anaphylaxis

PHARMACOLOGIC MANAGEMENT OF ANAPHYLAXIS
 
Outpatient setting

First-line treatment

•  EPINEPHRINE, IM; auto-injector or 1:1000 solution

  º  Weight 10–25kg: 0.15mg epinephrine autoinjector, IM (anterior-lateral thigh)

  º  Weight>25kg: 0.3mg epinephrine autoinjector, IM (anterior-lateral thigh)

  º  Epinephrine (1:1000 solution) IM, 0.01mg/kg per dose; max 0.5mg per dose (anterior-lateral thigh)

  º  May need to repeat epinephrine dose every 5–15 minutes

Adjunctive treatment

•  Bronchodilator (β2-agonist): ALBUTEROL

  º  MDI (Children: 4–8 puffs; Adults: 8 puffs) or

  º  Nebulized solution (Children: 1.5mL; Adults: 3mL) every 20 minutes or continuously as needed

•  H1 antihistamine: DIPHENHYDRAMINE

  º  1–2mg/kg per dose; max 50mg IV or PO (oral liquid is more readily absorbed than tablets)

  º  Alternative dosing may be used with a less-sedating second generation antihistamine

•  Supplemental oxygen therapy

•  IV fluids in large volumes if patient presents with orthostasis, hypotension, or incomplete response to IM epinephrine

•  Place the patient in recumbent position if tolerated, with the lower extremities elevated

Hospital-based setting

First-line treatment

•  EPINEPHRINE IM (as above, outpatient setting), consider continuous epinephrine infusion for persistent hypotension (ideally with continuous non-invasive monitoring of blood pressure and heart rate); alternatives are endotracheal or intra-osseous epinephrine

Adjunctive treatment

•  Bronchodilator (β2-agonist): ALBUTEROL

  º  MDI (Children: 4–8 puffs; Adults: 8 puffs) or

  º  Nebulized solution (Children: 1.5mL; Adults: 3mL) every 20 minutes or continuously as needed

•  H1 antihistamine: DIPHENHYDRAMINE

  º  1–2mg/kg per dose; max 50mg IV or PO (oral liquid is more readily absorbed than tablets)

  º  Alternative dosing may be used with a less-sedating second generation antihistamine

•  H2 antihistamine: RANITIDINE

  º  1–2mg/kg per dose; max 75–150mg PO and IV

•  Corticosteroids

  º  PREDNISONE: 1mg/kg; max 60–80mg PO or

  º  METHYLPREDNISOLONE: 1mg/kg; max 60–80mg IV

•  Vasopressors (other than epinephrine) for refractory hypotension, titrate to effect

•  GLUCAGON for refractory hypotension, titrate to effect

  º  Children: 20–30 micrograms/kg

  º  Adults: 1–5 mg

  º  May repeat dose or followed by infusion of 5–15 micrograms/min

•  ATROPINE for bradycardia, titrate to effect

•  Supplemental oxygen therapy

•  IV fluids in large volumes if patient presents with orthostasis, hypotension, or incomplete response to IM epinephrine

•  Place the patient in recumbent position if tolerated, with the lower extremities elevated

Therapy at discharge

First-line treatment

•  EPINEPHRINE, auto-injector prescription (2 doses) and instructions

•  Education on avoidance of allergen

•  Follow-up with primary care physician

•  Consider referral to an allergist

Adjunctive treatment

•  H1 antihistamine: DIPHENHYDRAMINE every 6 hours for 2–3 days; alternative dosing with a non-sedating second generation antihistamine

•  H2 antihistamine: RANITIDINE twice daily for 2–3 days

•  Corticosteroid: PREDNISONE daily for 2–3 days

NOTES

**These treatments often occur concomitantly, and are not meant to be sequential, with the exception of epinephrine as first-line treatment.

Adapted from Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol 2010; 126(6):1105–18.

(Rev. 7/2012)

close

Next Article in Clinical Charts

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs